Blink Biomedical (Group)

https://www.blinkmedical.com

BliNK Biomedical SAS will leverage its B cell technology to develop proprietary human antibodies targeting immuno-oncology and oncology up to clinical stages. Anti-infective diseases will be addressed through on-going partnerships with pharmaceutical companies. BliNK Biomedical SAS’ powerful B cell technology will enable the isolation of antibody-producing cells for difficult targets for which other platforms have failed to deliver. This cutting-edge technology will be based on the combination of two validated platforms, BliNK Therapeutics’ IVV and Valneva’s VIVA|Screen®, which have already both succeeded in delivering high quality human antibodies. With the combined highly efficient process, an unprecedented capability to screen and identify extremely rare antibody-secreting cells will be achieved. This unique capability represents a major competitive advantage compared to other technologies. BliNK Therapeutics Ltd’s technology has been developed by Facundo Batista, Head of the Lymphocyte Interaction Laboratory at London Research Institute, Cancer Research UK. The technology provides a new way of activating the immune system’s B cells to produce antibodies in response to a specific antigen even when the ‘parent’ B cells are rare or when the antigens are hard for B cells to detect. Valneva’s antibody technology was successfully applied for a series of infectious and non-infectious targets and allowed the discovery of a large number of highly potent native human antibodies. In 2010, Valneva signed a strategic collaborative & commercial agreement with Sanofi Pasteur, the vaccine division of Sanofi, to discover and develop fully human monoclonal antibodies against some selected infectious diseases. Valneva recently announced the signing of a new research collaboration and license agreement with a leading global animal health care company to discover antibodies from animal Blymphocytes. *

	Start	2014-12-11 reorganised
	Predecessor	Valneva (Group)
	Industry	therapeutic antibody
	Industry 2	Viva\|Screen™ technology
	Person	Elands, Jacobus P. M. (Jack) (Emergence Therapeutics 202006 CEO + Blink Biomedical 201510– CEO before Amakem CEO)
	Person 2	Staatz-Granzer, Irina (Staatz Business Development & Strategy 2006– + U3 Pharma 200804 CEO)

	Region	Marseille
	Country	France
	Street	17 boulevard Cieussa
	City	13007 Marseille
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«:

		Record changed: 2024-02-12